Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Περιεχόμενα  Φάρμακα Α - Ζ  Συγχορήγηση

SOMAVERT Powder and solvent for solution for injection (2019)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

SOMAVERT 10 mg powder and solvent for solution for injection. SOMAVERT 15 mg powder and solvent for solution for injection. SOMAVERT 20 mg powder and solvent for solution for injection. SOMAVERT 25 mg ...

Qualitative and quantitative composition

SOMAVERT 10 mg powder and solvent for solution for injection: One vial contains 10 mg of pegvisomant. After reconstitution, 1 ml of solution contains 10 mg of pegvisomant.* Excipient with known effect: ...

Pharmaceutical form

Powder and solvent for solution for injection (powder for injection). The powder is white to slightly off-white.

Therapeutic indications

Treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize ...

Posology and method of administration

Treatment should be initiated under the supervision of a physician experienced in the treatment of acromegaly. Posology A loading dose of 80 mg pegvisomant should be administered subcutaneously under medical ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Special warnings and precautions for use

Growth hormone-secreting tumours Growth hormone-secreting pituitary tumours may sometimes expand, causing serious complications (for example, visual field defects). Treatment by pegvisomant does not reduce ...

Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed. It should be considered whether to continue treatment with somatostatin analogues. The use of this medicine in combination with other medicinal products for ...

Fertility, pregnancy and lactation

Women of childbearing potential See section 4.4. Pregnancy For pegvisomant no clinical data on exposed pregnancies are available. Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal ...

Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

Undesirable effects

Summary of the safety profile The list below contains adverse reactions seen in clinical trials with SOMAVERT. In clinical studies, for patients treated with pegvisomant (n=550), the majority of adverse ...

Overdose

There is limited experience of overdose with pegvisomant. In the one reported incident of acute overdose, where 80 mg/day was administered for 7 days, the patient experienced a slight increase in fatigue ...

Pharmacodynamic properties

Pharmacotherapeutic group: Other anterior pituitary lobe hormones and analogues ATC code: H01AX01 Mechanism of action Pegvisomant is an analogue of human growth hormone that has been genetically modified ...

Pharmacokinetic properties

Absorption Absorption of pegvisomant following subcutaneous administration is slow and prolonged, and peak serum pegvisomant concentrations are not generally attained until 33-77 hours after administration. ...

Preclinical safety data

Non-clinical data revealed no special hazard for humans based on studies of repeated dose toxicity in rat and monkey. However, due to the marked pharmacological response in monkey, systemic exposures higher ...

List of excipients

Powder: Glycine Mannitol (E421) Disodium phosphate anhydrous Sodium dihydrogen phosphate monohydrate Solvent: Water for Injections

Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Shelf life

Shelf life: 3 years. After reconstitution, the product should be used immediately.

Special precautions for storage

Store the powder vial(s) in a refrigerator (2°C–8°C). Do not freeze. Keep the vial(s) in their outer carton in order to protect from light. Store the pre-filled syringe(s) below 30C or store in a refrigerator ...

Nature and contents of container

10 mg or 15 mg or 20 mg or 25 mg or 30 mg of pegvisomant in powder in a vial (type I flint glass) with a stopper (chlorobutylrubber) and 1 ml solvent (water for injections) in a pre-filled syringe (type ...

Special precautions for disposal and other handling

The syringe and safety needle used to administer the injection are provided with the medicinal product. Before attaching the supplied safety needle the syringe cap will need to be removed from the pre-filled ...

Marketing authorization holder

Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050, Bruxelles, Belgium

Marketing authorization number(s)

EU/1/02/240/001 10 mg 30 vials EU/1/02/240/002 15 mg 30 vials EU/1/02/240/004 20 mg 1 vial EU/1/02/240/003 20 mg 30 vials EU/1/02/240/009 25 mg 1 vial EU/1/02/240/010 25 mg 30 vials EU/1/02/240/011 30 ...

Date of first authorization / renewal of the authorization

Date of first authorization: 13 November 2002 Date of latest renewal: 20 September 2007

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: